Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded generics Proprietary brands sold in more than 40 countries - across Europe, the Middle East, North America and Asia, through pharmacies, hospitals, retail chains and e-commerce Addressable markets of approximately $946 billion - the six product categories and two service markets in which the Company competes are estimated by third-party research at approximately $946 billion in 2025, projected to reach approximately $1.76 trillion by 2033 Infection control gaining hospital and retail traction - C-Scrub listed at Tesco and Superdrug and tested under EN 12791 for surgical hand disinfection; C-Sept PRO adopted across leading Greek hospital groups; C-ScrubVet launched into animal health Gross margins of over 70% expected across key brands - including Sky Premium Life, the 18 Series, C-Scrub and C-Sept Manufactured at GMP-certified facilities on two continents - principally at Cana Laboratories' EU GMP-licensed, EMA-certified facility in Athens, and at GMP-certified, FDA-registered facilities in the United States Supported by integrated services - contract manufacturing at Cana Laboratories, pharmaceutical distribution in Greece and the United Kingdom, ZipDoctor telehealth in the United States, and AI-enabled research and development A platform for future brands - registrations, distribution partners, retail and hospital listings and manufacturing capacity already in place are expected to support further launches into existing markets at lower cost and in less time CHICAGO, IL / ACCESS Newswire / October 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an overview of its brand portfolio and the global markets it addresses. The portfolio comprises more than 15 proprietary brands and product lines and 10 branded generics across five product categories, sold in more than 40 countries through pharmacies, hospitals, retail chains and e-commerce.